Atlas Trials

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Clinical trial NCT04506645 · COMPLETED

Trial details

NCT number
NCT04506645
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2020-09-01
Primary completion
2022-12-14
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.